MX383544B - Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas - Google Patents

Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas

Info

Publication number
MX383544B
MX383544B MX2019015029A MX2019015029A MX383544B MX 383544 B MX383544 B MX 383544B MX 2019015029 A MX2019015029 A MX 2019015029A MX 2019015029 A MX2019015029 A MX 2019015029A MX 383544 B MX383544 B MX 383544B
Authority
MX
Mexico
Prior art keywords
treatment
positive bacteria
streptococcus
detection
gram positive
Prior art date
Application number
MX2019015029A
Other languages
English (en)
Spanish (es)
Inventor
Chad Euler
Daniel Gilmer
Jonathan Schmitz
Vincent A Fischetti
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of MX383544B publication Critical patent/MX383544B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2019015029A 2011-04-21 2012-04-20 Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas MX383544B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477836P 2011-04-21 2011-04-21
PCT/US2012/034456 WO2012145630A2 (en) 2011-04-21 2012-04-20 Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria

Publications (1)

Publication Number Publication Date
MX383544B true MX383544B (es) 2025-03-14

Family

ID=47042182

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2019015029A MX383544B (es) 2011-04-21 2012-04-20 Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
MX2013012241A MX336427B (es) 2011-04-21 2012-04-20 Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas.
MX2016000588A MX370442B (es) 2011-04-21 2012-04-20 Proteínas quiméricas de una lisina de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.
MX2021007008A MX2021007008A (es) 2011-04-21 2013-10-18 Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2013012241A MX336427B (es) 2011-04-21 2012-04-20 Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas.
MX2016000588A MX370442B (es) 2011-04-21 2012-04-20 Proteínas quiméricas de una lisina de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.
MX2021007008A MX2021007008A (es) 2011-04-21 2013-10-18 Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.

Country Status (12)

Country Link
US (7) US9034322B2 (OSRAM)
EP (2) EP3252155A1 (OSRAM)
JP (4) JP6139509B2 (OSRAM)
CN (4) CN108578685A (OSRAM)
AU (3) AU2012245357B2 (OSRAM)
CA (1) CA2833409A1 (OSRAM)
DK (1) DK2699253T3 (OSRAM)
ES (1) ES2682670T3 (OSRAM)
HK (2) HK1244503A1 (OSRAM)
IL (4) IL228869B (OSRAM)
MX (4) MX383544B (OSRAM)
WO (1) WO2012145630A2 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
US20140179594A1 (en) * 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
NL2007038C2 (en) * 2011-07-04 2013-01-07 Vereniging Voor Christelijk Hoger Onderwijs System and method for predicting the viability of a body tissue in a patient, and measuring device used therein.
CA3187222A1 (en) * 2012-05-09 2013-11-14 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophage lysin
KR102310387B1 (ko) * 2012-05-09 2021-10-13 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
CN104073478A (zh) * 2014-06-13 2014-10-01 上海交通大学 杀灭革兰氏阳性菌的酶抗生素及其制备、用途
CN106659748B (zh) * 2014-06-26 2021-08-31 洛克菲勒大学 不动杆菌属溶素
CN104726439B (zh) * 2015-04-13 2017-11-14 武汉菲吉乐科生物科技有限公司 一种广谱的链球菌裂解酶及其应用
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
EP3328417A4 (en) * 2015-07-31 2019-02-06 The Regents of The University of California MYCOBACTERIUM LYSTERASE: A NEW TREATMENT FOR AKNE
US20180353575A1 (en) * 2015-09-13 2018-12-13 The Rockefeller University Clostridium difficile bacteriophage lysins for detection and treatment of clostridium difficile bacteria infection
EP4151228A3 (en) 2015-09-17 2023-06-14 Contrafect Corporation Lysin polypeptides active against gram-negative bacteria
CA3023730A1 (en) 2016-05-12 2017-11-16 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
AU2018300062A1 (en) * 2017-07-10 2020-01-30 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
CA3085644A1 (en) 2017-12-12 2019-06-20 Contrafect Corporation Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa
CN117866859A (zh) * 2018-01-05 2024-04-12 阿兹特拉公司 葡萄球菌属细菌的营养缺陷型菌株
CN112118861A (zh) * 2018-02-26 2020-12-22 康特拉费克特公司 修饰的PlySs2溶素及其用途
KR102073088B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-2 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073094B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-3 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073086B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-1 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
WO2020037031A1 (en) * 2018-08-17 2020-02-20 Becton, Dickinson And Company Antimicrobial susceptibility testing using microdroplets
US11674961B2 (en) 2018-10-12 2023-06-13 Quidel Corporation Extraction reagent for use in an assay for detection of group A Streptococcus
AU2020244764A1 (en) * 2019-03-22 2021-10-14 Contrafect Corporation Method of treating infective endocarditis
AU2020256258A1 (en) * 2019-04-05 2021-11-04 Contrafect Corporation Lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa, in the presence of human serum
EP3980049A4 (en) * 2019-04-11 2023-07-19 Contrafect Corporation METHOD OF TREATMENT AND PREVENTION OF BONE AND JOINT INFECTIONS
EP4157306A4 (en) * 2020-05-19 2024-07-03 Contrafect Corporation MODIFIED PLYSS2 LYSINES AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA
US20220087266A1 (en) * 2020-09-22 2022-03-24 Mars, Incorporated Compositions and methods for controlling mycotoxin production
CN114480299B (zh) * 2020-10-27 2023-08-29 暨南大学 一种蜡样芽胞杆菌噬菌体及其应用
CN116762008A (zh) * 2020-11-25 2023-09-15 美国控股实验室公司 用于使用感染因子来检测微生物的方法和系统
CN112760312B (zh) * 2021-01-20 2022-06-17 华中农业大学 一种裂解革兰氏阳性菌的裂解酶plyssX609及其应用
WO2023049747A1 (en) * 2021-09-22 2023-03-30 Elanco Us Inc. Streptococcus suis lytic enzyme compositions and methods of use thereof
KR102742550B1 (ko) * 2022-07-26 2024-12-18 주식회사 인트론바이오테크놀로지 연쇄상구균에 대하여 용균 활성을 갖는 항균단백질
WO2024059184A1 (en) * 2022-09-16 2024-03-21 The Johns Hopkins University Machine learning systems and related aspects for the detection of disease states
CN116640754B (zh) * 2023-07-21 2023-10-10 临沂大学 一种链球菌前噬菌体裂解酶lys224及应用
CN117866985B (zh) * 2023-10-11 2024-08-30 圆因(北京)生物科技有限公司 一种用于表达耐甲氧西林金黄色葡萄球菌内溶素的rna序列
CN118272361A (zh) * 2024-05-13 2024-07-02 内蒙古农业大学 一种发酵粘液乳杆菌噬菌体裂解酶LysLFP01及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278378A (en) 1962-04-19 1966-10-11 Schindler Charles Alvin Staphylococcus-derived antibiotic
US3398056A (en) 1964-07-10 1968-08-20 Mead Johnson & Co Process for producing lysostaphin by fermentation
US3594284A (en) 1968-06-04 1971-07-20 Mead Johnson & Co Lysostaphin fermentation with accelerated time cycle
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
DE3546806C2 (OSRAM) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
AU8108587A (en) 1986-10-08 1988-05-06 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
US4948580A (en) 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
JPH02258718A (ja) 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd ペースト状基剤及び製剤
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
US20060292135A1 (en) * 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
CN1352567A (zh) * 1999-02-25 2002-06-05 新眼界诊断公司 预防性和治疗性治疗链球菌感染的方法
CA2366712A1 (en) 1999-02-25 2000-08-31 Vincent Fischetti A means for the prophylactic and therapeutic treatment of streptococcal infections
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
EP1501925A4 (en) 2002-05-17 2006-10-25 New Horizons Diagnostics Corp IDENTIFICATION OF A LYTIC ENZYME ASSOCIATED WITH A PHAGE TO DETECT AND ELIMINATE RAPIDLY AND SPECIFICALLY BACILLUS ANTHRACIS
US8326388B2 (en) 2002-10-31 2012-12-04 Toshiba Medical Systems Corporation Method and apparatus for non-invasive measurement of living body characteristics by photoacoustics
WO2004043376A2 (en) * 2002-11-07 2004-05-27 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
WO2004104213A2 (en) * 2003-05-15 2004-12-02 The Rockefeller University Nucleic acids and polypeptides of c1 bacteriophage and uses thereof
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
WO2005089527A2 (en) 2004-03-24 2005-09-29 The Rockefeller University Lytic enzymes and spore surface antigen for detection and treatment of bacillus anthracis bacteria and spores
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
ATE491026T1 (de) * 2005-08-24 2010-12-15 Univ Rockefeller Ply-gbs-lysinmutanten
IE20060488A1 (en) * 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent
DE102006061002A1 (de) * 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
US20100310522A1 (en) 2007-11-26 2010-12-09 Plant Bioscience Limited Novel Polypeptides Having Endolysin Activity and Uses Thereof
EP2103308A1 (de) * 2008-03-20 2009-09-23 PhytoLine GmbH Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen
EP3263588A1 (en) 2008-07-03 2018-01-03 The Rockefeller University Isolated staphylococcus-specific soluble binding molecule
AU2009273845B2 (en) * 2008-07-24 2016-02-04 The United State Of America, As Represented By The Secretary Of Agriculture Triple acting antimicrobials that are refractory to resistance development
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
KR101016918B1 (ko) * 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
WO2011091412A1 (en) * 2010-01-25 2011-07-28 Alere Scarborough, Inc. A25 bacteriophage lysin
US20140179594A1 (en) * 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock

Also Published As

Publication number Publication date
JP6587655B2 (ja) 2019-10-09
NZ616945A (en) 2015-11-27
US20200149025A1 (en) 2020-05-14
WO2012145630A2 (en) 2012-10-26
WO2012145630A3 (en) 2014-05-01
JP6284976B2 (ja) 2018-02-28
EP2699253A4 (en) 2015-07-01
ES2682670T3 (es) 2018-09-21
NZ731111A (en) 2019-06-28
CN115887627A (zh) 2023-04-04
IL287530A (en) 2021-12-01
US20220127590A1 (en) 2022-04-28
EP2699253B1 (en) 2018-03-28
EP2699253A2 (en) 2014-02-26
JP2017171686A (ja) 2017-09-28
IL228869A0 (en) 2013-12-31
JP6735796B2 (ja) 2020-08-05
AU2017202728B2 (en) 2019-04-04
AU2017202728A1 (en) 2017-05-18
CN107189997A (zh) 2017-09-22
JP2016147903A (ja) 2016-08-18
IL266476A (en) 2019-06-30
CA2833409A1 (en) 2012-10-26
US20150267185A1 (en) 2015-09-24
US20170298334A1 (en) 2017-10-19
JP6139509B2 (ja) 2017-05-31
US11155799B2 (en) 2021-10-26
CN103857410A (zh) 2014-06-11
NZ713076A (en) 2017-05-26
IL228869B (en) 2019-05-30
AU2012245357B2 (en) 2017-06-08
CN108578685A (zh) 2018-09-28
HK1247956A1 (en) 2018-10-05
HK1244503A1 (zh) 2018-08-10
MX336427B (es) 2016-01-18
AU2012245357A1 (en) 2013-11-14
US9034322B2 (en) 2015-05-19
AU2019204660B2 (en) 2021-01-28
AU2019204660A1 (en) 2019-07-18
IL271300A (en) 2020-01-30
US10544407B2 (en) 2020-01-28
JP2014518849A (ja) 2014-08-07
US20230167427A9 (en) 2023-06-01
MX2021007008A (es) 2022-06-02
DK2699253T3 (en) 2018-07-16
US20200002694A1 (en) 2020-01-02
IL266476B (en) 2020-01-30
US20140072549A1 (en) 2014-03-13
JP2019022504A (ja) 2019-02-14
US20220064615A1 (en) 2022-03-03
MX2013012241A (es) 2014-05-07
MX370442B (es) 2019-12-13
US9914915B2 (en) 2018-03-13
IL271300B (en) 2021-12-01
US11111484B2 (en) 2021-09-07
EP3252155A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
MX383544B (es) Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
WO2013122888A3 (en) Methods of treating bacterial infections
BR112012033212A2 (pt) uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica
WO2013184755A3 (en) Seca inhibitors and methods of making and using thereof
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
GB201013307D0 (en) Anti-microbial metal organic framework
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
MX2012010671A (es) Compuestos antiinfecciosos.
SG11201405829WA (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
LT3251678T (lt) Benzoksaborolo dariniai, skirti bakterinių infekcijų gydymui
HK1198689A1 (en) Antibody formulations and methods
IN2014MN02437A (OSRAM)
WO2013036783A3 (en) Methods for treating intrapulmonary infections
MX2011006803A (es) Agentes antibacterianos novedosos para el tratamiento de infecciones gram positivas.
NZ741342A (en) Daptomycin formulations and uses thereof
PH12014502680A1 (en) Polysaccharide compositions and methods of use
WO2012020108A3 (en) Multimeric inhibitors of viral fusion and uses thereof
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
WO2012047582A3 (en) Compositions useful for target, detection, imaging and treatment, and methods of production and use thereof
PH12015501131A1 (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states
MX2012004282A (es) Composiciones farmaceuticas.
WO2013009678A3 (en) Compositions and methods for the treatment of norovirus infection
HK1206594A1 (en) Materials and methods for prevention and treatment of viral infections
WO2013155320A3 (en) Use of microbial gene products to prevent or treat microbial infections
WO2015063608A3 (en) Prevention and dispersion of biolfilm